Deborah Bitterfield CEO and Founder of Lindy Biosciences, shares her vision for our groundbreaking collaboration with Novartis. Join us as we re-envision the future of drug delivery and elevate the standard of care in how people receive biotherapeutic treatments. ? #DrugDelivery #Innovation #Pharma #Biotech
Lindy Biosciences, Inc.
研究服务
Durham，NC 1,090 位关注者
Advanced Formulation Technologies for Better Biotherapeutics
关于我们
Lindy Biosciences is a development-stage protein therapeutic formulations company. Our core technology, Microglassification?, produces spherical, dense, stable particles of a therapeutic protein. These protein particles are ideal for long-term storage, or for incorporation into drug delivery formulations such as suspensions(for high-concentration delivery of antibodies), encapsulation (for sustained/controlled release), or dry powder pulmonary delivery.
- 网站
-
https://www.lindybio.com
Lindy Biosciences, Inc.的外部链接
- 所属行业
- 研究服务
- 规模
- 11-50 人
- 总部
- Durham，NC
- 类型
- 私人持股
- 创立
- 2017
- 领域
- Drug Delivery、Formulation Technology、Drug Stability和Particle Engineering
地点
-
主要
获取路线
US，NC，Durham，27713
Lindy Biosciences, Inc.员工
动态
-
We are thrilled to announce a major milestone: Lindy Biosciences has entered into a global licensing and collaboration agreement with Novartis for our cutting-edge drug formulation and delivery platform. This deal marks a significant step forward in our mission to return patients to control and independence. ?? Solving for the limitations in biologics delivery systems: Novartis gains multi-target exclusive global rights to our microglassification suspension technology, designed to deliver high-dose biologics by convenient subcutaneous injections. ?? A new pace on patient care: This collaboration is set to enhance self-administration of high-concentration treatments, potentially improving patient outcomes and compliance. ? Learn More: https://lnkd.in/eKSv_sCs ? #Biotech #DrugDelivery #Innovation #Healthcare #Biologics #Pharma #News
-
-
We're excited to welcome Gary Vinson as our new Chief Operating Officer! ? Gary brings over 20 years of experience in the pharmaceutical, CRO/CMO, and biotechnology industries. He has a proven track record of leading product development operations at both clinical and commercial scales. Before joining Lindy Biosciences, Gary held key leadership roles where he contributed to novel developments in cell therapies and specialty pharmaceuticals. ? Gary is joining Lindy Biosciences to implement the strategies and functional activities necessary for?product development. He will lead internal and external company operations, including all development and manufacturing performed by CDMOs to support our biotech and pharmaceutical partnerships. ? “I am pleased to be joining Lindy Biosciences as COO to lead the next steps in the growth of the company as we further develop our proprietary microglassification drug delivery technology and elevate the standards of care by how patients receive biotherapeutic treatments,” said Gary. ? We’re thrilled to have Gary on board as we continue to change the rhythm of patient care! https://lnkd.in/eNJk-Qge ? #Leadership #Biotech #Innovation ?
-
-
Our CEO and Founder Deborah Bitterfield, PhD, is thrilled to attend and speak at Technical Session VII during #CRS2024! During “Breaking the Aqueous Limit: Engineered Particles for Self-Delivery of High-Concentration Suspensions of Biologics,” Deborah will discuss the challenges and breakthroughs in this cutting-edge research, showcasing Lindy Biosciences’ commitment to advancing therapeutic interventions in drug delivery, potentially improving patient outcomes and compliance. Thanks for the opportunity, Controlled Release Society! I'm looking forward to the discussion with Roberta Cavalli, Phd, Dong Yun Lee, Hélder A. Santos, and Yoon Yen PhD. #Innovation #Biotech #DrugDevelopment
Don't miss your chance to attend Technical Session Vll on Friday, July 12, from 8:00-10:00am CET. This session provides a great opportunity for attendees to gain understanding of siRNA nanocarriers to reach undruggable oncoproteins such as KRAS, MSC-derived EVs (MSC-EVs) to treat liver fibrosis, exploiting the protein corona for plasma proteome profiling in diagnostics, advances in controlled transdermal delivery of antitubercular drugs, and the use of fucoidan, a natural polysaccharide, to engineer anti-tumor fucoidan-based nanoparticles. Speaker Highlight: Deborah Bitterfield, PdD Roberta Cavalli, PhD Dong Yun Lee, PhD Hélder A. Santos, DSc Yoon Yeo, PhD Full Schedule: https://ow.ly/9pFj50SrLO1 #CRS2024 #deliveryscience #pharma #drugdelivery #scientist #scienceandtechnology #researchandevelopment
-
-
Ever wonder how cutting-edge science is transforming drug development? Meet Lindy Biosciences. We are pioneers in drug delivery of biologics, reshaping the future of medicine. Our innovative solutions and technology enhance drug formulation and delivery. Our goal? To improve patient comfort and convenience, boost treatment compliance, and reduce healthcare costs. Stay tuned to learn more about our groundbreaking work! https://www.lindybio.com/ #Innovation #Biotech #DrugDevelopment #PatientCentric
-